Karolina Bilska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karolina Bilska has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Monika Dmitrzak-Weglarz
Department of Psychiatric Genetics, Medical Biology Center, Poznan University of Medical Sciences, Poznan, Poland
11 shared publications - Ewa Marzena Kalemba
Institute of Dendrology, Polish Academy of Sciences, Kornik, Poland
6 shared publications - Natalia Wojciechowska
Institute of Dendrology, Polish Academy of Sciences, Kornik, Poland
6 shared publications - Agnieszka Słopień
Department of Child and Adolescent Psychiatry, Karol Jonscher Clinical Hospital, Poznan University of Medical Sciences, 27/33 Szpitalna St., 60-572 Poznan, Poland
5 shared publications - Edyta Reszka
Department of Biophysics of Environmental Pollution, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Łódź, Poland
5 shared publications - Maria Skibinska
Department of Neural Engineering and Space Medicine, Collegium Medicum, University of Zielona Góra, 65-001 Zielona Góra, Poland
5 shared publications
Latest Publications
- 15 February 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 376, 487-496
BDNF and proBDNF serum levels during antidepressant treatment in adolescent girls with a first-lifetime episode of depression: A prospective case-controlled study
- 15 February 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 376, 487-496
BDNF and proBDNF serum levels during antidepressant treatment in adolescent girls with a first-lifetime episode of depression: A prospective case-controlled study
- Open Access
- 14 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (6) , 3281
Biomarkers of Depression among Adolescent Girls: BDNF and Epigenetics
Alterations in brain-derived neurotrophic factor (BDNF) expression have been suggested to mediate the influence of environmental factors on the emergence of depression through epigenetic modifications. However, research on this subject in the developmental population is lacking and the pathophysiology of adolescent depression remains unclear. We aimed to investigate the alterations in BDNF expression and global DNA methylation in depression among adolescent girls. Thirty female inpatients with the initial diagnosis of depression were assessed before and after the period of antidepressant treatment and compared with thirty age-matched healthy controls. The assessment involved BDNF and proBDNF serum levels, the BDNF gene exon IV promoter methylation, and global DNA methylation. The methylation level in the BDNF gene exon IV promoter was significantly lower in the studied group compared with the control and correlated negatively with the severity of depression. The test distinguished the studied group from the controls with a sensitivity of 37% and specificity of 90%. The differences were no longer present after the period of antidepressant treatment. No differences in the global DNA methylation, BDNF, and proBDNF levels were found. We concluded that decreased methylation in the BDNF exon IV promoter could be considered as a biomarker of a depression state among adolescent girls.
- 14 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (6) , 3281
Open AccessBiomarkers of Depression among Adolescent Girls: BDNF and Epigenetics
Alterations in brain-derived neurotrophic factor (BDNF) expression have been suggested to mediate the influence of environmental factors on the emergence of depression through epigenetic modifications. However, research on this subject in the developmental population is lacking and the pathophysiology of adolescent depression remains unclear. We aimed to investigate the alterations in BDNF expression and global DNA methylation in depression among adolescent girls. Thirty female inpatients with the initial diagnosis of depression were assessed before and after the period of antidepressant treatment and compared with thirty age-matched healthy controls. The assessment involved BDNF and proBDNF serum levels, the BDNF gene exon IV promoter methylation, and global DNA methylation. The methylation level in the BDNF gene exon IV promoter was significantly lower in the studied group compared with the control and correlated negatively with the severity of depression. The test distinguished the studied group from the controls with a sensitivity of 37% and specificity of 90%. The differences were no longer present after the period of antidepressant treatment. No differences in the global DNA methylation, BDNF, and proBDNF levels were found. We concluded that decreased methylation in the BDNF exon IV promoter could be considered as a biomarker of a depression state among adolescent girls.
- Open Access
- 1 January 2024
- Published by Termedia Sp. z.o.o. in Issues of Rehabilitation, Orthopaedics, Neurophysiology and Sport Promotion - IRONS
- Vol. 49 (4) , 23-34
THE BDNF GENE PROMOTER METHYLATION IN THE COURSE OF ANTIDEPRESSANT TREATMENT IN ADOLESCENT GIRLS WITH FIRST-LIFETIME DEPRESSIVE EPISODE: A PROSPECTIVE STUDY.
Introduction Epigenetic mechanisms regulating the level of BDNF gene expression correlate with achieving remission in the course of Major Depressive Disorder in adults. Studies in this area may contribute to individualization of antidepressant pharmacotherapy and increasing its effectiveness, but the amount of data on this subject in the pediatric population is limited. To date, no study has prospectively investigated changes in the BDNF gene methylation level following antidepressant treatment in adolescents. Aim Therefore, we aimed to examine the BDNF gene exon IV promoter methylation status in the group of adolescents treated for the first-lifetime depressive episode. Moreover, we aimed to verify the usefulness of BDNF methylation status as a predictor of treatment outcome. Material and Methods Our study included 30 female inpatients diagnosed with depression who underwent antidepressant treatment. Before starting treatment and after a minimum of 6 weeks, the level of methylation of the BDNF gene exon IV promoter was examined. Results. No statistically significant difference in the level of BDNF gene methylation before or after treatment was observed, and the usefulness of BDNF gene methylation as a prognostic factor for treatment response was not proven. Conclusions Further studies on a larger group of patients are necessary to verify whether the dynamics of methylation changes in the BDNF gene mirrors the results obtained in adults. Studies on this subject are essential to increase the effectiveness of depression treatment in adolescent patients.
- 1 January 2024
- Published by Termedia Sp. z.o.o. in Issues of Rehabilitation, Orthopaedics, Neurophysiology and Sport Promotion - IRONS
- Vol. 49 (4) , 23-34
Open AccessTHE BDNF GENE PROMOTER METHYLATION IN THE COURSE OF ANTIDEPRESSANT TREATMENT IN ADOLESCENT GIRLS WITH FIRST-LIFETIME DEPRESSIVE EPISODE: A PROSPECTIVE STUDY.
Introduction Epigenetic mechanisms regulating the level of BDNF gene expression correlate with achieving remission in the course of Major Depressive Disorder in adults. Studies in this area may contribute to individualization of antidepressant pharmacotherapy and increasing its effectiveness, but the amount of data on this subject in the pediatric population is limited. To date, no study has prospectively investigated changes in the BDNF gene methylation level following antidepressant treatment in adolescents. Aim Therefore, we aimed to examine the BDNF gene exon IV promoter methylation status in the group of adolescents treated for the first-lifetime depressive episode. Moreover, we aimed to verify the usefulness of BDNF methylation status as a predictor of treatment outcome. Material and Methods Our study included 30 female inpatients diagnosed with depression who underwent antidepressant treatment. Before starting treatment and after a minimum of 6 weeks, the level of methylation of the BDNF gene exon IV promoter was examined. Results. No statistically significant difference in the level of BDNF gene methylation before or after treatment was observed, and the usefulness of BDNF gene methylation as a prognostic factor for treatment response was not proven. Conclusions Further studies on a larger group of patients are necessary to verify whether the dynamics of methylation changes in the BDNF gene mirrors the results obtained in adults. Studies on this subject are essential to increase the effectiveness of depression treatment in adolescent patients.
- Open Access
Metabolic Syndrome and Adipokines Profile in Bipolar Depression
Metabolic syndrome (MS) is a growing social, economic, and health problem. MS coexists with nearly half of all patients with affective disorders. This study aimed to evaluate the neurobiological parameters (clinical, anthropometric, biochemical, adipokines levels, and ultrasound of carotid arteries) and their relationship with the development of MS in patients with bipolar disorder. The study group consisted of 70 patients (50 women and 20 men) hospitalized due to episodes of depression in the course of bipolar disorders. The Hamilton Depression Rating Scale was used to assess the severity of the depression symptoms in an acute state of illness and after six weeks of treatment. The serum concentration of adipokines was determined using an ELISA method. The main finding of this study is that the following adipokines correlated with MS in the bipolar depression women group: visfatin, S100B, and leptin had a positive correlation, whereas adiponectin, leptin-receptor, and adiponectin/leptin ratio showed a negative correlation. Moreover, the adiponectin/leptin ratio showed moderate to strong negative correlation with insulin level, BMI, waist circumference, triglyceride level, treatment with metformin, and a positive moderate correlation with HDL. The adiponectin/leptin ratio may be an effective tool to assess MS in depressed female bipolar patients.
Open AccessMetabolic Syndrome and Adipokines Profile in Bipolar Depression
Metabolic syndrome (MS) is a growing social, economic, and health problem. MS coexists with nearly half of all patients with affective disorders. This study aimed to evaluate the neurobiological parameters (clinical, anthropometric, biochemical, adipokines levels, and ultrasound of carotid arteries) and their relationship with the development of MS in patients with bipolar disorder. The study group consisted of 70 patients (50 women and 20 men) hospitalized due to episodes of depression in the course of bipolar disorders. The Hamilton Depression Rating Scale was used to assess the severity of the depression symptoms in an acute state of illness and after six weeks of treatment. The serum concentration of adipokines was determined using an ELISA method. The main finding of this study is that the following adipokines correlated with MS in the bipolar depression women group: visfatin, S100B, and leptin had a positive correlation, whereas adiponectin, leptin-receptor, and adiponectin/leptin ratio showed a negative correlation. Moreover, the adiponectin/leptin ratio showed moderate to strong negative correlation with insulin level, BMI, waist circumference, triglyceride level, treatment with metformin, and a positive moderate correlation with HDL. The adiponectin/leptin ratio may be an effective tool to assess MS in depressed female bipolar patients.
- Open Access
- 19 September 2022
- Published by MDPI AG in Psychiatry International
- Vol. 3 (3) , 248-263
Ghrelin and Obestatin in Adolescent Patients with Anorexia Nervosa: Is There an Association with Disordered Eating, Depression, and Obsessive-Compulsive Symptoms?
Anorexia nervosa (AN) is an eating disorder characterized by restrictive eating and significant weight loss. In the course of AN, changes are observed in appetite regulation, including orexigenic ghrelin and potentially anorexigenic obestatin. The study aimed to determine if any changes in serum ghrelin and obestatin levels during treatment of AN are observed, while investigating the correlations between these peptides and the severity of disturbed eating attitudes, depression, and anxiety. Thirty adolescent inpatients with AN (examined twice: before hospitalization treatment AN-BT and after treatment AN-AT) and thirty healthy age- and height-matched girls (CG) participated in the study. Anthropometric, serum ghrelin and obestatin concentrations and psychometric evaluations (Eating Attitudes Test 26 Item-EAT-26, Beck Depression Inventory-BDI, Hamilton Depression Rating Scale-HDRS, and Yale Brown Obsessive-Compulsive Scale-Y-BOCS) were performed. The study revealed significantly higher ghrelin and obestatin levels in AN-BT than in AN-AT. A trend toward lower levels during treatment provided partial normalizations. Analyzing correlations in the AN-BT vs. CG group, correlations of peptides with EAT-26, BDI, and HDRS scores were detected. These results suggest a potential role for ghrelin and obestatin in the context of defense mechanisms regulating appetite and body weight in the course of AN and in terms of psychopathological changes co-occurring with this eating disorder.
- 19 September 2022
- Published by MDPI AG in Psychiatry International
- Vol. 3 (3) , 248-263
Open AccessGhrelin and Obestatin in Adolescent Patients with Anorexia Nervosa: Is There an Association with Disordered Eating, Depression, and Obsessive-Compulsive Symptoms?
Anorexia nervosa (AN) is an eating disorder characterized by restrictive eating and significant weight loss. In the course of AN, changes are observed in appetite regulation, including orexigenic ghrelin and potentially anorexigenic obestatin. The study aimed to determine if any changes in serum ghrelin and obestatin levels during treatment of AN are observed, while investigating the correlations between these peptides and the severity of disturbed eating attitudes, depression, and anxiety. Thirty adolescent inpatients with AN (examined twice: before hospitalization treatment AN-BT and after treatment AN-AT) and thirty healthy age- and height-matched girls (CG) participated in the study. Anthropometric, serum ghrelin and obestatin concentrations and psychometric evaluations (Eating Attitudes Test 26 Item-EAT-26, Beck Depression Inventory-BDI, Hamilton Depression Rating Scale-HDRS, and Yale Brown Obsessive-Compulsive Scale-Y-BOCS) were performed. The study revealed significantly higher ghrelin and obestatin levels in AN-BT than in AN-AT. A trend toward lower levels during treatment provided partial normalizations. Analyzing correlations in the AN-BT vs. CG group, correlations of peptides with EAT-26, BDI, and HDRS scores were detected. These results suggest a potential role for ghrelin and obestatin in the context of defense mechanisms regulating appetite and body weight in the course of AN and in terms of psychopathological changes co-occurring with this eating disorder.
- Open Access
Common and Unique Genetic Background between Attention-Deficit/Hyperactivity Disorder and Excessive Body Weight
Comorbidity studies show that children with ADHD have a higher risk of being overweight and obese than healthy children. This study aimed to assess the genetic alternations that differ between and are shared by ADHD and excessive body weight (EBW). The sample consisted of 743 Polish children aged between 6 and 17 years. We analyzed a unique set of genes and polymorphisms selected for ADHD and/or obesity based on gene prioritization tools. Polymorphisms in the KCNIP1, SLC1A3, MTHFR, ADRA2A, and SLC6A2 genes proved to be associated with the risk of ADHD in the studied population. The COMT gene polymorphism was one that specifically increased the risk of EBW in the ADHD group. Using the whole-exome sequencing technique, we have shown that the ADHD group contains rare and protein-truncating variants in the FBXL17, DBH, MTHFR, PCDH7, RSPH3, SPTBN1, and TNRC6C genes. In turn, variants in the ADRA2A, DYNC1H1, MAP1A, SEMA6D, and ZNF536 genes were specific for ADHD with EBW. In this way, we confirmed, at the molecular level, the existence of genes specifically predisposing to EBW in ADHD patients, which are associated with the biological pathways involved in the regulation of the reward system, intestinal microbiome, and muscle metabolism.
Open AccessCommon and Unique Genetic Background between Attention-Deficit/Hyperactivity Disorder and Excessive Body Weight
Comorbidity studies show that children with ADHD have a higher risk of being overweight and obese than healthy children. This study aimed to assess the genetic alternations that differ between and are shared by ADHD and excessive body weight (EBW). The sample consisted of 743 Polish children aged between 6 and 17 years. We analyzed a unique set of genes and polymorphisms selected for ADHD and/or obesity based on gene prioritization tools. Polymorphisms in the KCNIP1, SLC1A3, MTHFR, ADRA2A, and SLC6A2 genes proved to be associated with the risk of ADHD in the studied population. The COMT gene polymorphism was one that specifically increased the risk of EBW in the ADHD group. Using the whole-exome sequencing technique, we have shown that the ADHD group contains rare and protein-truncating variants in the FBXL17, DBH, MTHFR, PCDH7, RSPH3, SPTBN1, and TNRC6C genes. In turn, variants in the ADRA2A, DYNC1H1, MAP1A, SEMA6D, and ZNF536 genes were specific for ADHD with EBW. In this way, we confirmed, at the molecular level, the existence of genes specifically predisposing to EBW in ADHD patients, which are associated with the biological pathways involved in the regulation of the reward system, intestinal microbiome, and muscle metabolism.
- 1 September 2021
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 54 (06) , 261-268
Expression Biomarkers of Pharmacological Treatment Outcomes in Women with Unipolar and Bipolar Depression
Introduction This study aimed to find the expression biomarkers of pharmacological treatment response in a naturalistic hospital setting. Through gene expression profiling, we were able to find differentially-expressed genes (DEGs) in unipolar (UD) and bipolar (BD) depressed women. Methods We performed gene expression profiling in hospitalized women with unipolar (n=24) and bipolar depression (n=32) who achieved clinical improvement after pharmacological treatment (without any restriction). To identify DEGs in peripheral blood mononuclear cells (PBMCs), we used the SurePrint G3 Microarray and GeneSpring software. Results After pharmacological treatment, UD and BD varied in the number of regulated genes and ontological pathways. Also, the pathways of neurogenesis and synaptic transmission were significantly up-regulated. Our research focused on DEGs with a minimum fold change (FC) of more than 2. For both types of depression, 2 up-regulated genes, OPRM1 and CELF4 (p=0.013), were significantly associated with treatment response (defined as a 50% reduction on the Hamilton Depression Rating Scale [HDRS]). We also uncovered the SHANK3 (p=0.001) gene that is unique for UD and found that the RASGRF1 (p=0.010) gene may be a potential specific biomarker of treatment response for BD. Conclusion Based on transcriptomic profiling, we identified potential expression biomarkers of treatment outcomes for UD and BD. We also proved that the Ras-GEF pathway associated with long-term memory, female stress response, and treatment response modulation in animal studies impacts treatment efficacy in patients with BD. Further studies focused on the outlined genes may help provide predictive markers of treatment outcomes in UD and BD.
- 1 September 2021
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 54 (06) , 261-268
Expression Biomarkers of Pharmacological Treatment Outcomes in Women with Unipolar and Bipolar Depression
Introduction This study aimed to find the expression biomarkers of pharmacological treatment response in a naturalistic hospital setting. Through gene expression profiling, we were able to find differentially-expressed genes (DEGs) in unipolar (UD) and bipolar (BD) depressed women. Methods We performed gene expression profiling in hospitalized women with unipolar (n=24) and bipolar depression (n=32) who achieved clinical improvement after pharmacological treatment (without any restriction). To identify DEGs in peripheral blood mononuclear cells (PBMCs), we used the SurePrint G3 Microarray and GeneSpring software. Results After pharmacological treatment, UD and BD varied in the number of regulated genes and ontological pathways. Also, the pathways of neurogenesis and synaptic transmission were significantly up-regulated. Our research focused on DEGs with a minimum fold change (FC) of more than 2. For both types of depression, 2 up-regulated genes, OPRM1 and CELF4 (p=0.013), were significantly associated with treatment response (defined as a 50% reduction on the Hamilton Depression Rating Scale [HDRS]). We also uncovered the SHANK3 (p=0.001) gene that is unique for UD and found that the RASGRF1 (p=0.010) gene may be a potential specific biomarker of treatment response for BD. Conclusion Based on transcriptomic profiling, we identified potential expression biomarkers of treatment outcomes for UD and BD. We also proved that the Ras-GEF pathway associated with long-term memory, female stress response, and treatment response modulation in animal studies impacts treatment efficacy in patients with BD. Further studies focused on the outlined genes may help provide predictive markers of treatment outcomes in UD and BD.
- 27 April 2021
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 22 (10) , 744-756
Transcriptomic profiling as biological markers of depression – A pilot study in unipolar and bipolar women
A significant challenge in psychiatry is the differential diagnosis of depressive episodes in the course of mood disorders. Gene expression profiling may provide an opportunity for such distinguish...
- 27 April 2021
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 22 (10) , 744-756
Transcriptomic profiling as biological markers of depression – A pilot study in unipolar and bipolar women
A significant challenge in psychiatry is the differential diagnosis of depressive episodes in the course of mood disorders. Gene expression profiling may provide an opportunity for such distinguish...
- Open Access
- 26 April 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Molecular Regulation of the Melatonin Biosynthesis Pathway in Unipolar and Bipolar Depression
Melatonin is a neurohormone that maintains the circadian rhythms of the body. By regulating the secretion of other hormones and neurotransmitters, it acts as a pleiotropic modulator that affects, for example, reproductive, immune, cardiovascular, sleep, and wake systems and mood. Thus, synthetic melatonin has become an essential component in the treatment of depressive disorders. Although we know the pathway of melatonin action in the brain, we lack comprehensive cross-sectional studies on the periphery of depressed patients. This study aimed to comprehensively analyze the differences between healthy control subjects (n = 84) and unipolar and bipolar depression patients (n = 94), including an analysis of the melatonin pathway at the level of the genes and serum biomarkers. An innovative approach is a pilot study based on gene expression profiling carried out on clinical and cell culture models using agomelatine and melatonin. We confirmed the melatonin biosynthesis pathway's molecular regulation dysfunctions, with a specific pattern for unipolar and bipolar depression, at the AANAT gene, its polymorphisms (rs8150 and rs3760138), and examined the serum biomarkers (serotonin, AANAT, ASMT, and melatonin). The biological pathway analysis uncovered pathways and genes that were uniquely altered after agomelatine treatment in a clinical model and melatonin treatment in a cell culture model. In both models, we confirmed the immunomodulatory effect of melatonin agents in depression.
- 26 April 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessMolecular Regulation of the Melatonin Biosynthesis Pathway in Unipolar and Bipolar Depression
Melatonin is a neurohormone that maintains the circadian rhythms of the body. By regulating the secretion of other hormones and neurotransmitters, it acts as a pleiotropic modulator that affects, for example, reproductive, immune, cardiovascular, sleep, and wake systems and mood. Thus, synthetic melatonin has become an essential component in the treatment of depressive disorders. Although we know the pathway of melatonin action in the brain, we lack comprehensive cross-sectional studies on the periphery of depressed patients. This study aimed to comprehensively analyze the differences between healthy control subjects (n = 84) and unipolar and bipolar depression patients (n = 94), including an analysis of the melatonin pathway at the level of the genes and serum biomarkers. An innovative approach is a pilot study based on gene expression profiling carried out on clinical and cell culture models using agomelatine and melatonin. We confirmed the melatonin biosynthesis pathway's molecular regulation dysfunctions, with a specific pattern for unipolar and bipolar depression, at the AANAT gene, its polymorphisms (rs8150 and rs3760138), and examined the serum biomarkers (serotonin, AANAT, ASMT, and melatonin). The biological pathway analysis uncovered pathways and genes that were uniquely altered after agomelatine treatment in a clinical model and melatonin treatment in a cell culture model. In both models, we confirmed the immunomodulatory effect of melatonin agents in depression.
- Open Access
- 10 February 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (4) , 676
Differences in the Clinical Picture in Women with a Depressive Episode in the Course of Unipolar and Bipolar Disorder
Due to current depression prevalence, it is crucial to make the correct diagnosis as soon as possible. The study aimed to identify commonly available, easy to apply, and quick to interpret tools allowing for a differential diagnosis between unipolar and bipolar disorder. The study group includes women with long duration of unipolar (UP, N = 34) and bipolar (BP, N = 43) affective disorder. The diagnosis was established according to the DSM criteria using SCID questionnaire. Additional questionnaires were used to differentiate between UP and BP. BP patients had an earlier age of onset, were hospitalized more times, and more often had a family history of psychiatric disorders than UP (p-value < 0.05). Moreover, BP achieved a higher impulsiveness score and more frequently had experienced severe problems with close individuals. To our knowledge, this is the first publication presenting results of numerous questionnaires applied simultaneously in patients on clinical group. Several of them suggest the direction of clinical assessment, such as: the age of onset, family psychiatric burdens, history of stressful life events, learning problems, social and job relations. Further studies are necessary to confirm the utility of this approach.
- 10 February 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (4) , 676
Open AccessDifferences in the Clinical Picture in Women with a Depressive Episode in the Course of Unipolar and Bipolar Disorder
Due to current depression prevalence, it is crucial to make the correct diagnosis as soon as possible. The study aimed to identify commonly available, easy to apply, and quick to interpret tools allowing for a differential diagnosis between unipolar and bipolar disorder. The study group includes women with long duration of unipolar (UP, N = 34) and bipolar (BP, N = 43) affective disorder. The diagnosis was established according to the DSM criteria using SCID questionnaire. Additional questionnaires were used to differentiate between UP and BP. BP patients had an earlier age of onset, were hospitalized more times, and more often had a family history of psychiatric disorders than UP (p-value < 0.05). Moreover, BP achieved a higher impulsiveness score and more frequently had experienced severe problems with close individuals. To our knowledge, this is the first publication presenting results of numerous questionnaires applied simultaneously in patients on clinical group. Several of them suggest the direction of clinical assessment, such as: the age of onset, family psychiatric burdens, history of stressful life events, learning problems, social and job relations. Further studies are necessary to confirm the utility of this approach.